Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events.

Wightman H. et al, (2025), PLoS Med, 22

Glucocorticoid-induced hyperglycaemia in hospitalised adults: A matched cohort study (2013-2023).

Golubic R. et al, (2025), Diabetes Obes Metab

Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes.

Sammons E. et al, (2025), BMJ Open, 15

Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.

Hanlon P. et al, (2025), JAMA

The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply.

Adler AI. et al, (2025), Lancet, 405

An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders

De Giorgi R. et al, (2025), Nature Mental Health

Cardiovascular Risk Prediction Scores in Type 1 Diabetes: A Systematic Review and Meta-Analysis

Erqou S. et al, (2025), JACC: Advances, 4

Glucocorticoid treatment and new-onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: A systematic review and meta-analysis.

Golubic R. et al, (2024), Diabet Med

The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors.

Klonoff DC. et al, (2024), J Diabetes Sci Technol

Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations.

Lugo-Palacios DG. et al, (2024), Health Econ

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.

Schilling WHK. et al, (2024), PLoS Med, 21

Examining the impact of structural uncertainty across ten type 2 diabetes models: Results from the 2022 Mount Hood Challenge.

Altunkaya J. et al, (2024), Value Health

Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults.

Koychev I. et al, (2024), BMJ Open, 14

Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).

Adler AI. et al, (2024), Lancet

Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.

Bidulka P. et al, (2024), BMJ, 385

Overcoming challenges in the economic evaluation of interventions to optimise antibiotic use

ROOPE L. et al, (2024), Communications Medicine

ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy.

Sammons EL. et al, (2024), Ophthalmology, 131, 526 - 533

ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy.

Sammons EL. et al, (2024), Ophthalmology

12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study

De Giorgi R. et al, (2024), eClinicalMedicine

Diabetes mellitus in Kabuki syndrome 1 on a background of post-transplant diabetes mellitus.

Chew Sue Mei S. et al, (2024), Endocrinology, diabetes & metabolism case reports, 2024, 23 - 133

Load More